The Adrenal Cortex

Williams Textbook of Endocrinology, Twelfth Edition

Volumn , Issue , 2011, Pages 479-544

  Stewart, Paul M ^a,b   Krone, Nils P ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883499684     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0324-5.00015-8     Document Type: Chapter

References (464)

1. B Eustachius (1774) Tabulae Anatomicae. B Lancisius,(Eds) Amsterdam
2. T Addison (1866) On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules. London: Highley
3. CE Brown-Sequard (1856) Recherches experimentales sur la physiologie et la pathologie des capsules surrenales. Arch Gen Med 5 385-401.
4. VC Medvei (1993) A History of Clinical Endocrinology. Pearl River, NY: Parthenon
5. PS Hench, EC Kendall, et al. (1949) The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 24 181-197.
6. SA Simpson and JF Tait (1955) Recent progress in methods of isolation, chemistry, and physiology of aldosterone. Recent Prog Horm Res 11 183-210.
7. CH Li, HM Evans and ME Simpson (1943) Adrenocorticotrophic hormone. J Biol Chem 149 413-424.
8. H Cushing (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50 137-195.
9. W Vale, J Spiess, C Rivier, et al. (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213 1394-1397.
10. JW Conn (1955) Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 3-17.
11. T Else and GD Hammer (2005) Genetic analysis of adrenal absence: agenesis and aplasia. Trends Endocrinol Metab 16 458.
12. S Mesiano and RB Jaffe (1997) Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev 18 378-403.
13. RB Jaffe, S Mesiano, R Smith, et al. (1998) The regulation and role of fetal adrenal development in human pregnancy. Endocr Res 24 919-926.
14. M Okamoto and H Takemori (2000) Differentiation and zonation of the adrenal cortex. Curr Opin Endocrinol Diab 7 122-127.
15. X Luo, Y Ikeda and KL Parker (1994) A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77 481-490.
16. JC Havelock, RJ Auchus and WE Rainey (2004) The rise in adrenal androgen biosynthesis: adrenarche. Semin Reprod Med 22 337-347.
17. T Remer, KR Boye, MF Hartmann, et al. (2005) Urinary markers of adrenarche: reference values in healthy subjects, aged 3-18 years. J Clin Endocrinol Metab 90 2015-2021.
18. IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC) and IUPAC-IUB Commission on Biochemical Nomenclature (CBN). Definitive rules for the nomenclature of steroids. Pure Appl Chem 31 285-322.
19. JT Gwynne and JF Strauss 3rd (1982) The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. Endocr Rev 3 299-329.
20. JR Faust, JL Goldstein and MS Brown (1977) Receptor-mediated uptake of low density lipoprotein and utilization of its cholesterol for steroid synthesis in cultured mouse adrenal cells. J Biol Chem 252 4861-4871.
21. JL Goldstein, RG Anderson and MS Brown (1979) Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279 679-685.
22. KT Landschulz, RK Pathak, A Rigotti, et al. (1996) Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 98 984-995.
23. DM Stocco and BJ Clark (1996) Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 17 221-244.
24. H Amri, H Li, M Culty, et al. (1999) The peripheral-type benzodiazepine receptor and adrenal steroidogenesis. Curr Opin Endocrinol Diabetes 6 179-184.
25. R Bernhardt (2000) The role of adrenodoxin in adrenal steroidogenesis. Curr Opin Endocrinol Diab 7 109-115.
26. WL Miller (2005) Minireview: Regulation of steroidogenesis by electron transfer. Endocrinology 146 2544-2550.
27. AH Payne and DB Hales (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25 947-970.
28. M Onoda and PF Hall (1982) Cytochrome b5 stimulates purified testicular microsomal cytochrome P-450 (C21 side-chain cleavage). Biochem Biophys Res Commun 108 454-460.
29. WL Miller (1988) Molecular biology of steroid hormone synthesis. Endocr Rev 9 295-318.
30. ME John, MC John, P Ashley, et al. (1984) Identification and characterization of cDNA clones specific for cholesterol side-chain cleavage cytochrome P-450. Proc Natl Acad Sci U S A 81 5628-5632.
31. MC Lorence, BA Murry, JM Trant, et al. (1990) Human 3 β-hydroxysteroid dehydrogenase/delta 5-4 isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 126 2493-2498.
32. KD Bradshaw, MR Waterman, RT Couch, et al. (1987) Characterization of complementary deoxyribonucleic acid for human adrenocortical 17 alpha-hydroxylase: a probe for analysis of 17 alpha-hydroxylase deficiency. Mol Endocrinol 1 348-354.
33. Y Nakamura, PJ Hornsby, P Casson, et al. (2009) Type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J Clin Endocrinol Metab 94 2192-2198.
34. PC White, MI New and B Dupont (1984) Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A 81 1986-1990.
35. SC Chua, P Szabo, A Vitek, et al. (1987) Cloning of cDNA encoding steroid 11 β-hydroxylase (P450c11). Proc Natl Acad Sci U S A 84 7193-7197.
36. E Mornet, J Dupont, A Vitek, et al. (1989) Characterization of two genes encoding human steroid 11 β-hydroxylase (P-450(11) β). J Biol Chem 264 20961-20967.
37. KM Curnow, MT Tusie-Luna, L Pascoe, et al. (1991) The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 5 1513-1522.
38. CA Strott (2002) Sulfonation and molecular action. Endocr Rev 23 703-732.
39. PK Siiteri and PC MacDonald (1963) The utilization of dehydroisoandrosterone sulphate for estrogen synthesis during human pregnancy. Steroids 2 713-730.
40. B Lamolet, AM Pulichino, T Lamonerie, et al. (2001) A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104 849-859.
41. AI Smith and JW Funder (1988) Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev 9 159-179.
42. RA Donald (1980) ACTH and related peptides. Clin Endocrinol (Oxf) 12 491-524.
43. AB Bicknell, K Lomthaisong, RJ Woods, et al. (2001) Characterization of a serine protease that cleaves pro-gamma-melanotropin at the adrenal to stimulate growth. Cell 105 903-912.
44. I Suzuki, RD Cone, S Im, et al. (1996) Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 137 1627-1633.
45. CR DeBold, WE Nicholson and DN Orth (1988) Immunoreactive proopiomelanocortin (POMC) peptides and POMC-like messenger ribonucleic acid are present in many rat nonpituitary tissues. Endocrinology 122 2648-2657.
46. Y de Keyzer, F Lenne, JF Massias, et al. (1990) Pituitary-like proopiomelanocortin transcripts in human Leydig cell tumors. J Clin Invest 86 871-877.
47. AJ Clark, PM Lavender, P Coates, et al. (1990) In vitro and in vivo analysis of the processing and fate of the peptide products of the short proopiomelanocortin mRNA. Mol Endocrinol 4 1737-1743.
48. Y de Keyzer, X Bertagna, JP Luton, et al. (1989) Variable modes of proopiomelanocortin gene transcription in human tumors. Mol Endocrinol 3 215-223.
49. AJ Clark, PM Lavender, GM Besser, et al. (1989) Pro-opiomelanocortin mRNA size heterogeneity in ACTH-dependent Cushing's syndrome. J Mol Endocrinol 2 3-9.
50. A Picon, X Bertagna and Y de Keyzer (1999) Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors. Oncogene 18 2627-2633.
51. J Newell-Price, P King and AJ Clark (2001) The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol 15 338-348.
52. A Zhou, BT Bloomquist and RE Mains (1993) The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. J Biol Chem 268 1763-1769.
53. PM Stewart, S Gibson, SR Crosby, et al. (1994) ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) 40 199-204.
54. RL Oliver, JR Davis and A White (2003) Characterisation of ACTH related peptides in ectopic Cushing's syndrome. Pituitary 6 119-126.
55. AP Coll, IS Farooqi, BG Challis, et al. (2004) Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 89 2557-2562.
56. JR Lundblad and JL Roberts (1988) Regulation of proopiomelanocortin gene expression in pituitary. Endocr Rev 9 135-158.
57. DN Orth (1992) Corticotropin-releasing hormone in humans. Endocr Rev 13 164-191.
58. AL Taylor and LM Fishman (1988) Corticotropin-releasing hormone. N Engl J Med 319 213-222.
59. FA Antoni (1986) Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev 7 351-378.
60. S Shibahara, Y Morimoto, Y Furutani, et al. (1983) Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 2 775-779.
61. Y Furutani, Y Morimoto, S Shibahara, et al. (1983) Cloning and sequence analysis of cDNA for ovine corticotropin-releasing factor precursor. Nature 301 537-540.
62. R Chen, KA Lewis, MH Perrin, et al. (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90 8967-8971.
63. A Sasaki, S Sato, O Murakami, et al. (1987) Immunoreactive corticotropin-releasing hormone present in human plasma may be derived from both hypothalamic and extrahypothalamic sources. J Clin Endocrinol Metab 65 176-182.
64. EA Campbell, EA Linton, CD Wolfe, et al. (1987) Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition. J Clin Endocrinol Metab 64 1054-1059.
65. EA Linton, CD Wolfe, DP Behan, et al. (1988) A specific carrier substance for human corticotrophin releasing factor in late gestational maternal plasma which could mask the ACTH-releasing activity. Clin Endocrinol (Oxf) 28 315-324.
66. C Rivier, J Rivier and W Vale (1982) Inhibition of adrenocorticotropic hormone secretion in the rat by immunoneutralization of corticotropin-releasing factor. Science 218 377-379.
67. RL Hauger and G Aguilera (1993) Regulation of pituitary corticotropin releasing hormone (CRH) receptors by CRH: interaction with vasopressin. Endocrinology 133 1708-1714.
68. T Watanabe, Y Oki and DN Orth (1989) Kinetic actions and interactions of arginine vasopressin, angiotensin-II, and oxytocin on adrenocorticotropin secretion by rat anterior pituitary cells in the microperifusion system. Endocrinology 125 1921-1931.
69. A Bateman, A Singh, T Kral, et al. (1989) The immune-hypothalamic-pituitary-adrenal axis. Endocr Rev 10 92-112.
70. GP Chrousos (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332 1351-1362.
71. DW Ray, SG Ren and S Melmed (1996) Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line: role of STAT pathway. J Clin Invest 97 1852-1859.
72. R Udelsman, JA Norton, SE Jelenich, et al. (1987) Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab 64 986-994.
73. GM Vaughan, RA Becker, JP Allen, et al. (1982) Cortisol and corticotrophin in burned patients. J Trauma 22 263-273.
74. HR Fish, B Chernow and JT O'Brian (1986) Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycemia: a review. Metabolism 35 763-780.
75. A Luger, PA Deuster, SB Kyle, et al. (1987) Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise: physiologic adaptations to physical training. N Engl J Med 316 1309-1315.
76. G Aguilera (1994) Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 15 321-350.
77. ED Weitzman, D Fukushima, C Nogeire, et al. (1971) Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 33 14-22.
78. JD Veldhuis, A Iranmanesh, ML Johnson, et al. (1990) Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 71 452-463.
79. PM Horrocks, AF Jones, WA Ratcliffe, et al. (1990) Patterns of ACTH and cortisol pulsatility over twenty-four hours in normal males and females. Clin Endocrinol (Oxf) 32 127-134.
80. DB Boivin, JF Duffy, RE Kronauer, et al. (1996) Dose-response relationships for resetting of human circadian clock by light. Nature 379 540-542.
81. CA Czeisler, M Dumont, JF Duffy, et al. (1992) Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet 340 933-936.
82. D Desir, E Van Cauter, VS Fang, et al. (1981) Effects of “jet lag” on hormonal patterns: I. Procedures, variations in total plasma proteins, and disruption of adrenocorticotropin-cortisol periodicity. J Clin Endocrinol Metab 52 628-641.
83. LG Davis, R Arentzen, JM Reid, et al. (1986) Glucocorticoid sensitivity of vasopressin mRNA levels in the paraventricular nucleus of the rat. Proc Natl Acad Sci U S A 83 1145-1149.
84. ME Keller-Wood and MF Dallman (1984) Corticosteroid inhibition of ACTH secretion. Endocr Rev 5 1-24.
85. JC Buckingham, CD John, E Solito, et al. (2006) Annexin 1, glucocorticoids, and the neuroendocrine-immune interface. Ann N Y Acad Sci 1088 396-409.
86. SW Lamberts, JW Koper, P Biemond, et al. (1992) Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab 74 313-321.
87. TJ Cole, JA Blendy, AP Monaghan, et al. (1995) Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 9 1608-1621.
88. KG Mountjoy, LS Robbins, MT Mortrud, et al. (1992) The cloning of a family of genes that encode the melanocortin receptors. Science 257 1248-1251.
89. LA Metherell, JP Chapple, S Cooray, et al. (2005) Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 37 166-170.
90. AJ Clark, LF Chan, TT Chung, et al. (2009) The genetics of familial glucocorticoid deficiency. Best Pract Res Clin Endocrinol Metab 23 159-165.
91. BA Cooke (1999) Signal transduction involving cyclic AMP-dependent and cyclic AMP-independent mechanisms in the control of steroidogenesis. Mol Cell Endocrinol 151 25-35.
92. JJ Enyeart, B Mlinar and JA Enyeart (1993) T-type Ca2+ channels are required for adrenocorticotropin-stimulated cortisol production by bovine adrenal zona fasciculata cells. Mol Endocrinol 7 1031-1040.
93. M Ehrhart-Bornstein, JP Hinson, SR Bornstein, et al. (1998) Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 19 101-143.
94. Y Munari-Silem, MC Lebrethon, I Morand, et al. (1995) Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations. J Clin Invest 95 1429-1439.
95. ER Simpson and MR Waterman (1988) Regulation of the synthesis of steroidogenic enzymes in adrenal cortical cells by ACTH. Annu Rev Physiol 50 427-440.
96. MR Waterman and LJ Bischof (1997) Cytochromes P450 12: diversity of ACTH (cAMP)-dependent transcription of bovine steroid hydroxylase genes. FASEB J 11 419-427.
97. WE Rainey (1999) Adrenal zonation: clues from 11β-hydroxylase and aldosterone synthase. Mol Cell Endocrinol 151 151-160.
98. C Longcope (1986) Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 15 213-228.
99. F Labrie, A Belanger, J Simard, et al. (1995) DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci 774 16-28.
100. D Liu and JS Dillon (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277 21379-21388.
101. F Hammer, S Subtil, P Lux, et al. (2005) No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. J Clin Endocrinol Metab 90 3600-3605.
102. TJ McKenna, U Fearon, D Clarke, et al. (1997) A critical review of the origin and control of adrenal androgens. Baillieres Clin Obstet Gynaecol 11 229-248.
103. C Weinberger, SM Hollenberg, MG Rosenfeld, et al. (1985) Domain structure of human glucocorticoid receptor and its relationship to the v-erb-A oncogene product. Nature 318 670-672.
104. JL Arriza, C Weinberger, G Cerelli, et al. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237 268-275.
105. JA Gustafsson, J Carlstedt-Duke, L Poellinger, et al. (1987) Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 8 185-234.
106. J Zhou and JA Cidlowski (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70 407-417.
107. L Pascual-Le Tallec and M Lombes (2005) The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 19 2211-2221.
108. WB Pratt (1993) The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 268 21455-21458.
109. M Beato and A Sanchez-Pacheco (1996) Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17 587-609.
110. CM Bamberger, HM Schulte and GP Chrousos (1996) Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17 245-261.
111. NJ McKenna, RB Lanz and BW O'Malley (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20 321-344.
112. T Rhen and JA Cidlowski (2005) Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 353 1711-1723.
113. R Schule, P Rangarajan, S Kliewer, et al. (1990) Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62 1217-1226.
114. LI McKay and JA Cidlowski (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20 435-459.
115. JW Funder (1993) Aldosterone action. Annu Rev Physiol 55 115-130.
116. BC Rossier and RJ Alpern (1999) Cell and molecular biology of epithelial transport. Curr Opin Nephrol Hypertens 8 579-580.
117. F Verrey, JP Kraehenbuhl and BC Rossier (1989) Aldosterone induces a rapid increase in the rate of Na,K-ATPase gene transcription in cultured kidney cells. Mol Endocrinol 3 1369-1376.
118. SY Chen, A Bhargava, L Mastroberardino, et al. (1999) Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A 96 2514-2519.
119. CR Edwards, PM Stewart, D Burt, et al. (1988) Localisation of 11 β-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet 2 986-989.
120. JW Funder, PT Pearce, R Smith, et al. (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 583-585.
121. JW Funder (2002) New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 144 S8-11.
122. Y Iwasaki, Y Aoki, M Katahira, et al. (1997) Non-genomic mechanisms of glucocorticoid inhibition of adrenocorticotropin secretion: possible involvement of GTP-binding protein. Biochem Biophys Res Commun 235 295-299.
123. JW Funder (2005) The nongenomic actions of aldosterone. Endocr Rev 26 313-321.
124. GL Hammond (1990) Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev 11 65-79.
125. A Roitman, S Bruchis, B Bauman, et al. (1984) Total deficiency of corticosteroid-binding globulin. Clin Endocrinol (Oxf) 21 541-548.
126. CL Smith, SG Power and GL Hammond (1992) A Leu-His substitution at residue 93 in human corticosteroid binding globulin results in reduced affinity for cortisol. J Steroid Biochem Mol Biol 42 671-676.
127. DK Fukushima, HL Bradlow, L Hellman, et al. (1960) Metabolic transformation of hydrocortisone-4-C14 in normal men. J Biol Chem 235 2246-2252.
128. PC White, T Mune and AK Agarwal (1997) 11 β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18 135-156.
129. JW Tomlinson, EA Walker, IJ Bujalska, et al. (2004) 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25 831-866.
130. M Quinkler and PM Stewart (2003) Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 88 2384-2392.
131. JS Moore, JP Monson, G Kaltsas, et al. (1999) Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84 4172-4177.
132. E Voccia, P Saenger, RE Peterson, et al. (1979) 6 β-hydroxycortisol excretion in hypercortisolemic states. J Clin Endocrinol Metab 48 467-471.
133. S Yamada and K Iwai (1976) Induction of hepatic cortisol-6-hydroxylase by rifampicin (Letter). Lancet 2 366-367.
134. JA Whitworth, PM Stewart, D Burt, et al. (1989) The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 31 355-361.
135. V Kyriazopoulou, O Parparousi and AG Vagenakis (1984) Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 59 1204-1206.
136. DJ Morris and AS Brem (1987) Metabolic derivatives of aldosterone. Am J Physiol 252 F365-F373.
137. C Edwards, A Hayman (1991) Enzyme protection of the mineralocorticoid receptor: evidence in favour of the hemi-acetal structure of aldosterone. JP Bonvalet, N Farman, M Lombès, et al., (Eds) Aldosterone Fundamental Aspects London: Colloque INSERM/John Libbey Eurotext 67-76.
138. W Stalmans and M Laloux (1979) Glucocorticoids and hepatic glycogen metabolism. JD Baxter, GG Rousseau,(Eds) Glucocorticoid Hormone Action New York, NY: Springer-Verlag 518-533.
139. LM Watts, VP Manchem, TA Leedom, et al. (2005) Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54 1846-1853.
140. K Chakravarty, H Cassuto, L Reshef, et al. (2005) Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol 40 129-154.
141. JM Olefsky (1975) Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 56 1499-1508.
142. H Hauner, G Entenmann, M Wabitsch, et al. (1989) Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84 1663-1670.
143. M Rebuffe-Scrive, M Krotkiewski, J Elfverson, et al. (1988) Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 67 1122-1128.
144. M Bronnegard, P Arner, L Hellstrom, et al. (1990) Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. Endocrinology 127 1689-1696.
145. IJ Bujalska, S Kumar and PM Stewart (1997) Does central obesity reflect “Cushing's disease of the omentum”? Lancet 349 1210-1213.
146. SJ Leibovich and R Ross (1975) The role of the macrophage in wound repair: a study with hydrocortisone and antimacrophage serum. Am J Pathol 78 71-100.
147. E Canalis (1996) Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. Clinical Review 83. J Clin Endocrinol Metab 81 3441-3447.
148. TP van Staa, HG Leufkens, L Abenhaim, et al. (2000) Use of oral corticosteroids in the United Kingdom. Q J Med 93 105-111.
149. PL Williams and M Corbett (1983) Avascular necrosis of bone complicating corticosteroid replacement therapy. Ann Rheum Dis 42 276-279.
150. RS Weinstein, RW Nicholas and SC Manolagas (2000) Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85 2907-2912.
151. MB Leonard, HI Feldman, J Shults, et al. (2004) Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351 868-875.
152. R Fraser, DL Davies and JM Connell (1989) Hormones and hypertension. Clin Endocrinol (Oxf) 31 701-746.
153. T Saruta, H Suzuki, M Handa, et al. (1986) Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 62 275-279.
154. D Marver (1984) Evidence of corticosteroid action along the nephron. Am J Physiol 246 F111-F123.
155. H Raff (1987) Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 252 R635-R644.
156. SH Peers and RJ Flower (1990) The role of lipocortin in corticosteroid actions. Am Rev Respir Dis 141 S18-S21.
157. BS McEwen, ER De Kloet and W Rostene (1986) Adrenal steroid receptors and actions in the nervous system. Physiol Rev 66 1121-1188.
158. RM Sapolsky, LC Krey and BS McEwen (1985) Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 5 1222-1227.
159. SJ Lupien, M de Leon, S de Santi, et al. (1998) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1 69-73.
160. TC Sandeep, JL Yau, AM MacLullich, et al. (2004) 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A 101 6734-6739.
161. T Hajszan, NJ MacLusky and C Leranth (2004) Dehydroepiandrosterone increases hippocampal spine synapse density in ovariectomized female rats. Endocrinology 145 1042-1045.
162. JL Yau, S Rasmuson, R Andrew, et al. (2003) Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 121 307-314.
163. AF Clark (1995) Steroids, ocular hypertension, and glaucoma. J Glaucoma 4 354-369.
164. J Messer, D Reitman, HS Sacks, et al. (1983) Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 309 21-24.
165. AL Strickland, LE Underwood, SJ Voina, et al. (1972) Growth retardation in Cushing's syndrome. Am J Dis Child 123 207-213.
166. PL Ballard, R Ertsey, LW Gonzales, et al. (1996) Transcriptional regulation of human pulmonary surfactant proteins SP-B and SP-C by glucocorticoids. Am J Respir Cell Mol Biol 14 599-607.
167. RG Dluhy, SR Newmark, DP Lauler, et al. (1975) Pharmacology and chemistry of adrenal glucocorticoids. DL Azarnoff,(Eds) Steroid Therapy Philadelphia, PA: Saunders 1-14.
168. AW Meikle, JA Weed and FH Tyler (1975) Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays. J Clin Endocrinol Metab 41 717-721.
169. L Axelrod (1976) Glucocorticoid therapy. Medicine (Baltimore) 55 39-65.
170. L Wei, TM MacDonald and BR Walker (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141 764-770.
171. H Schacke, A Schottelius, WD Docke, et al. (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101 227-232.
172. CL Loprinzi, MD Jensen, NS Jiang, et al. (1992) Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 67 1160-1162.
173. NP Christy (1988) Corticosteroid withdrawal. CW Bardin,(Eds) Current Therapy in Endocrinology and Metabolism 3rd ed New York, NY: BC Decker 113-120.
174. KF Kane, P Emery, MC Sheppard, et al. (1995) Assessing the hypothalamo-pituitary-adrenal axis in patients on long-term glucocorticoid therapy: the short synacthen versus the insulin tolerance test. QJM 88 263-267.
175. TB Casale, HS Nelson, WE Stricker, et al. (2001) Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 87 379-385.
176. J Holme, JW Tomlinson, RA Stockley, et al. (2008) Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J 32 1047-1052.
177. RB Dixon and NP Christy (1980) On the various forms of corticosteroid withdrawal syndrome. Am J Med 68 224-230.
178. RL Hopkins and MC Leinung (2005) Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am 34 371-384. ix
179. W Walters, RM Wilder and EJ Kepler (1934) The suprarenal cortical syndrome with presentation of ten cases. Ann Surg 100 670-688.
180. CK Meador, GW Liddle, DP Island, et al. (1962) Cause of Cushing's syndrome in patients with tumors arising from “nonendocrine” tissue. J Clin Endocrinol Metab 22 693-703.
181. EJ Ross and DC Linch (1982) Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 2 646-649.
182. J Newell-Price, X Bertagna, AB Grossman, et al. (2006) Cushing's syndrome. Lancet 367 1605-1617.
183. BL Wajchenberg, A Bosco, MM Marone, et al. (1995) Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 80 2791-2794.
184. JP Luton, P Thieblot, JC Valcke, et al. (1977) Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab 45 488-495.
185. J Lado-Abeal, J Rodriguez-Arnao, JD Newell-Price, et al. (1998) Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 83 3083-3088.
186. WJ Jeffcoate, JT Silverstone, CR Edwards, et al. (1979) Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med 48 465-472.
187. LD Dorn, ES Burgess, B Dubbert, et al. (1995) Psychopathology in patients with endogenous Cushing's syndrome: “atypical” or melancholic features. Clin Endocrinol (Oxf) 43 433-442.
188. E Friess, K Wiedemann, A Steiger, et al. (1995) The hypothalamic-pituitary-adrenocortical system and sleep in man. Adv Neuroimmunol 5 111-125.
189. JR Lindsay, T Nansel, S Baid, et al. (2006) Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91 447-453.
190. JK Ferguson, RA Donald, TS Weston, et al. (1983) Skin thickness in patients with acromegaly and Cushing's syndrome and response to treatment. Clin Endocrinol (Oxf) 18 347-353.
191. DE Pleasure, GO Walsh and WK Engel (1970) Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol 22 118-125.
192. CM Plotz, AI Knowlton and C Ragan (1952) The natural history of Cushing's syndrome. Am J Med 13 597-614.
193. J Etxabe and JA Vazquez (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 40 479-484.
194. A Colao, R Pivonello, S Spiezia, et al. (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 84 2664-2672.
195. DC Dale and RG Petersdorf (1973) Corticosteroids and infectious diseases. Med Clin North Am 57 1277-1287.
196. BS Graham and WS Tucker Jr (1984) Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 101 334-338.
197. AT Hill, PM Stewart, EA Hughes, et al. (1998) Cushing's disease and tuberculosis. Respir Med 92 604-606.
198. MR Taskinen, EA Nikkila, R Pelkonen, et al. (1983) Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 57 619-626.
199. PM Stewart, BR Walker, G Holder, et al. (1995) 11 β-hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 80 3617-3620.
200. G Benker, M Raida, T Olbricht, et al. (1990) TSH secretion in Cushing's syndrome: relation to glucocorticoid excess, diabetes, goitre, and the “sick euthyroid syndrome.”. Clin Endocrinol (Oxf) 33 777-786.
201. M Saketos, N Sharma and NF Santoro (1993) Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. Biol Reprod 49 1270-1276.
202. F Sayegh and E Weigelin (1975) Intraocular pressure in Cushing's syndrome. Ophthalmic Res 7 390-394.
203. W Kelly (1996) Exophthalmos in Cushing's syndrome. Clin Endocrinol (Oxf) 45 167-170.
204. EA Bouzas, G Mastorakos, TC Friedman, et al. (1993) Posterior subcapsular cataract in endogenous Cushing syndrome: an uncommon manifestation. Invest Ophthalmol Vis Sci 34 3497-3500.
205. BM Biller (1994) Pathogenesis of pituitary Cushing's syndrome: pituitary versus hypothalamic. Endocrinol Metab Clin North Am 23 547-554.
206. C Gicquel, Y Le Bouc, JP Luton, et al. (1992) Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab 75 472-475.
207. BM Biller, JM Alexander, NT Zervas, et al. (1992) Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab 75 1303-1309.
208. YS Woo, AM Isidori, WZ Wat, et al. (2005) Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 90 4963-4969.
209. GW Liddle (1960) Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 20 1539-1560.
210. PM Stewart, R Penn, R Gibson, et al. (1992) Hypothalamic abnormalities in patients with pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 36 453-458.
211. RK Jex, JA van Heerden, PC Carpenter, et al. (1985) Ectopic ACTH syndrome: diagnostic and therapeutic aspects. Am J Surg 149 276-282.
212. TA Howlett, PL Drury, L Perry, et al. (1986) Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 24 699-713.
213. JW Findling and JB Tyrrell (1986) Occult ectopic secretion of corticotropin. Arch Intern Med 146 929-933.
214. I Ilias, DJ Torpy, K Pacak, et al. (2005) Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 90 4955-4962.
215. BL Wajchenberg, B Mendonca, B Liberman, et al. (1995) Ectopic ACTH syndrome. J Steroid Biochem Mol Biol 53 139-151.
216. AH Limper, PC Carpenter, B Scheithauer, et al. (1992) The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med 117 209-214.
217. WD Odell (1991) Ectopic ACTH secretion: a misnomer. Endocrinol Metab Clin North Am 20 371-379.
218. DW Ray, AC Littlewood, AJ Clark, et al. (1994) Human small cell lung cancer cell lines expressing the proopiomelanocortin gene have aberrant glucocorticoid receptor function. J Clin Invest 93 1625-1630.
219. RM Carey, SK Varma, CR Drake Jr, et al. (1984) Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome: a clinical, morphologic, and biochemical study. N Engl J Med 311 13-20.
220. OA Muller and K von Werder (1992) Ectopic production of ACTH and corticotropin-releasing hormone (CRH). J Steroid Biochem Mol Biol 43 403-408.
221. C Preeyasombat, V Sirikulchayanonta, P Mahachokelertwattana, et al. (1992) Cushing's syndrome caused by Ewing's sarcoma secreting corticotropin releasing factor-like peptide. Am J Dis Child 146 1103-1105.
222. DC Aron, JW Findling, PA Fitzgerald, et al. (1981) Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome: report of two cases and review of the literature. Am J Med 71 302-306.
223. JL Doppman, LK Nieman, WD Travis, et al. (1991) CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomous primary adrenal hypercortisolism. J Comput Assist Tomogr 15 773-779.
224. MH Samuels and DL Loriaux (1994) Cushing's syndrome and the nodular adrenal gland. Endocrinol Metab Clin North Am 23 555-569.
225. ND Sturrock, L Morgan and WJ Jeffcoate (1995) Autonomous nodular hyperplasia of the adrenal cortex: tertiary hypercortisolism? Clin Endocrinol (Oxf) 43 753-758.
226. AR Hermus, GF Pieters, AG Smals, et al. (1988) Transition from pituitary-dependent to adrenal-dependent Cushing's syndrome. N Engl J Med 318 966-970.
227. WF Young Jr, JA Carney, BU Musa, et al. (1989) Familial Cushing's syndrome due to primary pigmented nodular adrenocortical disease: reinvestigation 50 years later. N Engl J Med 321 1659-1664.
228. CA Stratakis, LS Kirschner and JA Carney (2001) Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86 4041-4046.
229. LS Kirschner, JA Carney, SD Pack, et al. (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26 89-92.
230. JM Kirk, CE Brain, DJ Carson, et al. (1999) Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 134 789-792.
231. CD Malchoff, D MacGillivray and DM Malchoff (1996) Adrenocorticotropic hormone-independent adrenal hyperplasia. Endocrinologist 6 79-85.
232. S Christopoulos, I Bourdeau and A Lacroix (2004) Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary 7 225-235.
233. AB Atkinson, AL Kennedy, DJ Carson, et al. (1985) Five cases of cyclical Cushing's syndrome. Br Med J (Clin Res Ed) 291 1453-1457.
234. F Mantero, CM Scaroni and NM Albiger (2004) Cyclic Cushing's syndrome: an overview. Pituitary 7 203-207.
235. MC Leinung and D Zimmerman (1994) Cushing's disease in children. Endocrinol Metab Clin North Am 23 629-639.
236. HL Storr, LF Chan, AB Grossman, et al. (2007) Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab 18 167-174.
237. JR Lindsay, J Jonklaas, EH Oldfield, et al. (2005) Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90 3077-3083.
238. C Wallace, EL Toth, RZ Lewanczuk, et al. (1996) Pregnancy-induced Cushing's syndrome in multiple pregnancies. J Clin Endocrinol Metab 81 15-21.
239. S Kirkman and DH Nelson (1988) Alcohol-induced pseudo-Cushing's disease: a study of prevalence with review of the literature. Metabolism 37 390-394.
240. PM Stewart, P Burra, CH Shackleton, et al. (1993) 11 β-hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease. J Clin Endocrinol Metab 76 748-751.
241. J Newell-Price, P Trainer, M Besser, et al. (1998) The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19 647-672.
242. AR Glass, KD Burman, WT Dahms, et al. (1981) Endocrine function in human obesity. Metabolism 30 89-104.
243. PM Stewart, A Boulton, S Kumar, et al. (1999) Cortisol metabolism in human obesity: impaired cortisone → cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84 1022-1027.
244. G Arnaldi, A Angeli, AB Atkinson, et al. (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88 5593-5602.
245. JW Findling and H Raff (2005) Screening and diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 34 385-402. ix-x
246. J Newell-Price, P Trainer, L Perry, et al. (1995) A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 43 545-550.
247. AH Hamrahian, TS Oseni and BM Arafah (2004) Measurements of serum free cortisol in critically ill patients. N Engl J Med 350 1629-1638.
248. H Raff, JL Raff and JW Findling (1998) Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 83 2681-2686.
249. M Yaneva, H Mosnier-Pudar, MA Dugue, et al. (2004) Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 89 3345-3351.
250. C Invitti, F Pecori Giraldi, M de Martin, et al. (1999) Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84 440-448.
251. JB Corcuff, A Tabarin, M Rashedi, et al. (1998) Overnight urinary free cortisol determination: a screening test for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 48 503-508.
252. C Cronin, D Igoe, MJ Duffy, et al. (1990) The overnight dexamethasone test is a worthwhile screening procedure. Clin Endocrinol (Oxf) 33 27-33.
253. AM Isidori, GA Kaltsas, S Mohammed, et al. (2003) Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 88 5299-5306.
254. AW Meikle (1982) Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin Endocrinol (Oxf) 16 401-408.
255. JA Yanovski, GB Cutler Jr, GP Chrousos, et al. (1993) Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269 2232-2238.
256. LK Nieman, BM Biller, JW Findling, et al. (2008) The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93 1526-1540.
257. JW Findling (1992) Clinical application of a new immunoradiometric assay for ACTH. Endocrinologist 2 360-365.
258. JB Tyrrell, JW Findling, DC Aron, et al. (1986) An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med 104 180-186.
259. P Biemond, FH de Jong and SW Lamberts (1990) Continuous dexamethasone infusion for seven hours in patients with the Cushing syndrome: a superior differential diagnostic test. Ann Intern Med 112 738-742.
260. JW Findling and JL Doppman (1994) Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 23 511-537.
261. PC Avgerinos, JA Yanovski, EH Oldfield, et al. (1994) The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med 121 318-327.
262. PJ Trainer, M Faria, J Newell-Price, et al. (1995) A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. J Clin Endocrinol Metab 80 412-417.
263. GP Chrousos, HM Schulte, EH Oldfield, et al. (1984) The corticotropin-releasing factor stimulation test: an aid in the evaluation of patients with Cushing's syndrome. N Engl J Med 310 622-626.
264. LK Nieman, EH Oldfield, R Wesley, et al. (1993) A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 77 1308-1312.
265. JR Lindsay and LK Nieman (2005) Differential diagnosis and imaging in Cushing's syndrome. Endocrinol Metab Clin North Am 34 403-421. x
266. EH Oldfield, JL Doppman, LK Nieman, et al. (1991) Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 325 897-905.
267. GA Kaltsas, MG Giannulis, JD Newell-Price, et al. (1999) A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 84 487-492.
268. WA Hall, MG Luciano, JL Doppman, et al. (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120 817-820.
269. M Korobkin and IR Francis (1995) Adrenal imaging. Semin Ultrasound CT MRI 16 317-330.
270. JM Miles, HW Wahner, PC Carpenter, et al. (1979) Adrenal scintiscanning with NP-59, a new radioiodinated cholesterol agent. Mayo Clin Proc 54 321-327.
271. WW de Herder, EP Krenning, CD Malchoff, et al. (1994) Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 96 305-312.
272. M Valimaki, R Pelkonen, L Porkka, et al. (1984) Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 20 229-236.
273. WF Young Jr and GB Thompson (2005) Laparoscopic adrenalectomy for patients who have Cushing's syndrome. Endocrinol Metab Clin North Am 34 489-499. xi
274. AA Kasperlik-Zaluska, BM Migdalska, S Zgliczynski, et al. (1995) Adrenocortical carcinoma: a clinical study and treatment results of 52 patients. Cancer 75 2587-2591.
275. B Allolio, S Hahner, D Weismann, et al. (2004) Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60 273-287.
276. M Terzolo, A Angeli, M Fassnacht, et al. (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356 2372-2380.
277. M Fassnacht and B Allolio (2009) Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23 273-289.
278. BM Biller, AB Grossman, PM Stewart, et al. (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93 2454-2462.
279. G Assie, H Bahurel, J Coste, et al. (2007) Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab 92 172-179.
280. PJ Jenkins, PJ Trainer, PN Plowman, et al. (1995) The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 80 165-171.
281. W Burch (1983) A survey of results with transsphenoidal surgery in Cushing's disease. N Engl J Med 308 103-104.
282. AL Utz, B Swearingen and BM Biller (2005) Pituitary surgery and postoperative management in Cushing's disease. Endocrinol Metab Clin North Am 34 459-478. xi
283. PJ Trainer, HS Lawrie, J Verhelst, et al. (1993) Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 38 73-78.
284. DR McCance, M Besser and AB Atkinson (1996) Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol (Oxf) 44 1-6.
285. MC Leinung, LA Kane, BW Scheithauer, et al. (1995) Long term follow-up of transsphenoidal surgery for the treatment of Cushing's disease in childhood. J Clin Endocrinol Metab 80 2475-2479.
286. SM Joshi, RJ Hewitt, HL Storr, et al. (2005) Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery 57 281-285. discussion 281-285
287. HL Storr, PN Plowman, PV Carroll, et al. (2003) Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab 88 34-37.
288. MK Aghi (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4 560-568.
289. JA Verhelst, PJ Trainer, TA Howlett, et al. (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 35 169-178.
290. DF Child, CW Burke, DM Burley, et al. (1976) Drug controlled of Cushing's syndrome; combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh) 82 330-341.
291. CG Semple, GH Beastall, CE Gray, et al. (1983) Trilostane in the management of Cushing's syndrome. Acta Endocrinol (Copenh) 102 107-110.
292. DR McCance, DR Hadden, L Kennedy, et al. (1987) Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 27 593-599.
293. AP Heaney, M Fernando, WH Yong, et al. (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8 1281-1287.
294. B Ambrosi, C Dall'Asta, S Cannavo, et al. (2004) Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151 173-178.
295. M Boscaro, WH Ludlam, B Atkinson, et al. (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94 115-122.
296. A Bhattacharyya, K Kaushal, DJ Tymms, et al. (2005) Steroid withdrawal syndrome after successful treatment of Cushing's syndrome: a reminder. Eur J Endocrinol 153 207-210.
297. AR Hermus, AG Smals, LM Swinkels, et al. (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 80 2859-2865.
298. MF Keil, DP Merke, R Gandhi, et al. (2009) Quality of life in children and adolescents 1 year after cure of Cushing syndrome: a prospective study. Clin Endocrinol (Oxf) 71 326-333.
299. E Charmandari, T Kino, E Souvatzoglou, et al. (2004) Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. J Clin Endocrinol Metab 89 1939-1949.
300. W Oelkers (1996) Adrenal insufficiency. N Engl J Med 335 1206-1212.
301. W Arlt and B Allolio (2003) Adrenal insufficiency. Lancet 361 1881-1893.
302. RM Carey (1997) The changing clinical spectrum of adrenal insufficiency. Ann Intern Med 127 1103-1105.
303. C Betterle, C Dal Pra, F Mantero, et al. (2002) Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 23 327-364.
304. G Piedrola, JL Casado, E Lopez, et al. (1996) Clinical features of adrenal insufficiency in patients with acquired immunodeficiency syndrome. Clin Endocrinol (Oxf) 45 97-101.
305. PU Freda and JP Bilezikian (1999) The hypothalamus-pituitary-adrenal axis in HIV disease. AIDS Read 9 43-50.
306. G Norbiato, M Galli, V Righini, et al. (1994) The syndrome of acquired glucocorticoid resistance in HIV infection. Baillieres Clin Endocrinol Metab 8 777-787.
307. DJ Seidenwurm, EB Elmer, LM Kaplan, et al. (1984) Metastases to the adrenal glands and the development of Addison's disease. Cancer 54 552-557.
308. VP Xarli, AA Steele, PJ Davis, et al. (1978) Adrenal hemorrhage in the adult. Medicine (Baltimore) 57 211-221.
309. E Lalli and P Sassone-Corsi (1999) DAX-1 and the adrenal cortex. Curr Opin Endocrinol Metab 6 185-190.
310. A Tabarin, JC Achermann, D Recan, et al. (2000) A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 105 321-328.
311. T Takahashi, Y Shoji, Y Shoji, et al. (1997) Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal hypoplasia congenita. J Pediatr 130 485-488.
312. KB Kaiserman, JM Nakamoto, ME Geffner, et al. (1998) Minipuberty of infancy and adolescent pubertal function in adrenal hypoplasia congenita. J Pediatr 133 300-302.
313. G Ozisik, G Mantovani, JC Achermann, et al. (2003) An alternate translation initiation site circumvents an amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita. J Clin Endocrinol Metab 88 417-423.
314. JC Achermann, M Ito, M Ito, et al. (1999) A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 22 125-126.
315. A Biason-Lauber and EJ Schoenle (2000) Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 67 1563-1568.
316. L Lin, P Philibert, B Ferraz-de-Souza, et al. (2007) Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function. J Clin Endocrinol Metab 92 991-999.
317. D Lourenco, R Brauner, L Lin, et al. (2009) Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 360 1200-1210.
318. A Scheuerle, F Greenberg and ER McCabe (1995) Dysmorphic features in patients with complex glycerol kinase deficiency. J Pediatr 126 764-767.
319. HW Moser, AE Moser, I Singh, et al. (1984) Adrenoleukodystrophy—survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol 16 628-641.
320. S Laureti, G Casucci, F Santeusanio, et al. (1996) X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 81 470-474.
321. J Mosser, AM Douar, CO Sarde, et al. (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361 726-730.
322. S Kemp, A Pujol, HR Waterham, et al. (2001) ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 18 499-515.
323. HW Moser, GV Raymond, SE Lu, et al. (2005) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 62 1073-1080.
324. AJ Clark, L McLoughlin and A Grossman (1993) Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 341 461-462.
325. C Tsigos, K Arai, W Hung, et al. (1993) Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 92 2458-2461.
326. A Huebner, LL Elias and AJ Clark (1999) ACTH resistance syndromes. J Pediatr Endocrinol Metab 12(Suppl 1)), 277-293.
327. A Tullio-Pelet, R Salomon, S Hadj-Rabia, et al. (2000) Mutant WD-repeat protein in triple-A syndrome. Nat Genet 26 332-335.
328. K Handschug, S Sperling, SJ Yoon, et al. (2001) Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet 10 283-290.
329. AM Pulichino, S Vallette-Kasic, C Couture, et al. (2003) Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes Dev 17 711-716.
330. S O'Rahilly, H Gray, PJ Humphreys, et al. (1995) Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 333 1386-1390.
331. H Krude, H Biebermann, W Luck, et al. (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19 155-157.
332. L Yaswen, N Diehl, MB Brennan, et al. (1999) Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5 1066-1070.
333. MT Dattani, JP Martinez-Barbera, PQ Thomas, et al. (1998) Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 19 125-133.
334. K Machinis, J Pantel, I Netchine, et al. (2001) Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 69 961-968.
335. M Lagerstrom-Fermer, M Sundvall, E Johnsen, et al. (1997) X-linked recessive panhypopituitarism associated with a regional duplication in Xq25-q26. Am J Hum Genet 60 910-916.
336. W Wu, JD Cogan, RW Pfaffle, et al. (1998) Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 18 147-149.
337. MS Cooper and PM Stewart (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348 727-734.
338. D Annane, V Sebille, G Troche, et al. (2000) A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283 1038-1045.
339. PE Marik, SM Pastores, D Annane, et al. (2008) Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36 1937-1949.
340. S Hahner, M Loeffler, M Fassnacht, et al. (2007) Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 92 3912-3922.
341. E Artavia-Loria, JL Chaussain, PF Bougneres, et al. (1986) Frequency of hypoglycemia in children with adrenal insufficiency. Acta Endocrinol Suppl (Copenh) 279 275-278.
342. F Laczi, T Janaky, T Ivanyi, et al. (1987) Osmoregulation of arginine-8-vasopressin secretion in primary hypothyroidism and in Addison's disease. Acta Endocrinol (Copenh) 114 389-395.
343. E Muls, R Bouillon, J Boelaert, et al. (1982) Etiology of hypercalcemia in a patient with Addison's disease. Calcif Tissue Int 34 523-526.
344. DJ Topliss, EL White and JR Stockigt (1980) Significance of thyrotropin excess in untreated primary adrenal insufficiency. J Clin Endocrinol Metab 50 52-56.
345. E Hagg, K Asplund and F Lithner (1987) Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf) 26 221-226.
346. J Lindholm and H Kehlet (1987) Re-evaluation of the clinical value of the 30 min ACTH test in assessing the hypothalamic-pituitary-adrenocortical function. Clin Endocrinol (Oxf) 26 53-59.
347. PM Clark, I Neylon, PR Raggatt, et al. (1998) Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol (Oxf) 49 287-292.
348. W Oelkers, S Diederich and V Bahr (1992) Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 75 259-264.
349. E Erturk, CA Jaffe and AL Barkan (1998) Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab 83 2350-2354.
350. PM Stewart, J Corrie, JR Seckl, et al. (1988) A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet 1 1208-1210.
351. DH Streeten, GH Anderson Jr and MM Bonaventura (1996) The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 81 285-290.
352. W Oelkers (1996) Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test. Eur J Endocrinol 135 27-33.
353. TA Abdu, TA Elhadd, R Neary, et al. (1999) Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 84 838-843.
354. R Kazlauskaite, AT Evans, CV Villabona, et al. (2008) Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 93 4245-4253.
355. AM Suliman, TP Smith, M Labib, et al. (2002) The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf) 56 533-539.
356. PM Stewart and PM Clark (2009) The low-dose corticotropin-stimulation test revisited: the less, the better? Nat Clin Pract Endocrinol Metab 5 68-69.
357. TM Fiad, JM Kirby, SK Cunningham, et al. (1994) The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 40 603-609.
358. R Schlaghecke, E Kornely, RT Santen, et al. (1992) The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326 226-230.
359. D Annane, V Sebille, C Charpentier, et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 862-871.
360. CL Sprung, D Annane, D Keh, et al. (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 111-124.
361. NV Esteban, T Loughlin, AL Yergey, et al. (1991) Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 72 39-45.
362. CM Feek, JG Ratcliffe, J Seth, et al. (1981) Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf) 14 451-458.
363. W Arlt, C Rosenthal, S Hahner, et al. (2006) Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 64 384-389.
364. K Lovas, CG Gjesdal, M Christensen, et al. (2009) Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 160 993-1002.
365. SR Peacey, CY Guo, AM Robinson, et al. (1997) Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 46 255-261.
366. TA Howlett (1997) An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 46 263-268.
367. TM Fiad, JD Conway, SK Cunningham, et al. (1996) The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf) 45 529-534.
368. W Arlt, F Callies, JC van Vlijmen, et al. (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341 1013-1020.
369. PC White and PW Speiser (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21 245-291.
370. DP Merke and SR Bornstein (2005) Congenital adrenal hyperplasia. Lancet 365 2125-2136.
371. EA Eugster, LA Dimeglio, JC Wright, et al. (2001) Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 138 26-32.
372. MS Cabrera, MG Vogiatzi and MI New (2001) Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 86 3070-3078.
373. R Azziz, D Dewailly and D Owerbach (1994) Nonclassic adrenal hyperplasia: current concepts. Clinical Review 56. J Clin Endocrinol Metab 78 810-815.
374. MI New (2006) Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 91 4205-4214.
375. M Bidet, C Bellanne-Chantelot, M-B Galand-Portier, et al. (2009) Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 94 1570-1578.
376. R Azziz, LA Sanchez, ES Knochenhauer, et al. (2004) Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89 453-462.
377. N Krone and W Arlt (2009) Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23 181-192.
378. PW Speiser, J Dupont, D Zhu, et al. (1992) Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90 584-595.
379. N Krone, A Braun, AA Roscher, et al. (2000) Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85 1059-1065.
380. RC Wilson, AB Mercado, KC Cheng, et al. (1995) Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 80 2322-2329.
381. RO Rocha, AE Billerbeck, EM Pinto, et al. (2008) The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clin Endocrinol (Oxf) 68 226-232.
382. LG Gomes, N Huang, V Agrawal, et al. (2009) Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 94 89-95.
383. MI New, F Lorenzen, AJ Lerner, et al. (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 57 320-326.
384. MG Forest, H Betuel and M David (1989) Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res 15 277-301.
385. Joint LWPES/ESPE CAH Working Group (2002) Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 87 4048-4053.
386. HF Meyer-Bahlburg (1999) What causes low rates of child-bearing in congenital adrenal hyperplasia? J Clin Endocrinol Metab 84 1844-1847.
387. JF Morgan, H Murphy, JH Lacey, et al. (2005) Long term psychological outcome for women with congenital adrenal hyperplasia: cross sectional survey. BMJ 330 340-341. discussion 341
388. HL Claahsen-van der Grinten, BJ Otten, MM Stikkelbroeck, et al. (2009) Testicular adrenal rest tumours in congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23 209-220.
389. PC Hindmarsh (2009) Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23 193-208.
390. DP Merke, GP Chrousos, G Eisenhofer, et al. (2000) Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343 1362-1368.
391. M Weise, SL Mehlinger, B Drinkard, et al. (2004) Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise. J Clin Endocrinol Metab 89 591-597.
392. JJ Van Wyk and EM Ritzen (2003) The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 88 2993-2998.
393. E Charmandari, GP Chrousos and DP Merke (2005) Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 18 97-101.
394. JR Seckl and WL Miller (1997) How safe is long-term prenatal glucocorticoid treatment? Jama 277 1077-1079.
395. S Pang, AT Clark, LC Freeman, et al. (1992) Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 75 249-253.
396. S Lajic, A Nordenstrom and T Hirvikoski (2008) Long-term outcome of prenatal treatment of congenital adrenal hyperplasia. Endocr Dev 13 82-98.
397. RE Cornean, PC Hindmarsh and CG Brook (1998) Obesity in 21-hydroxylase deficient patients. Arch Dis Child 78 261-263.
398. TM Volkl, D Simm, C Beier, et al. (2006) Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 117 e98-e105.
399. NM Stikkelbroeck, WJ Oyen, GJ van der Wilt, et al. (2003) Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 88 1036-1042.
400. H Falhammar, H Filipsson, G Holmdahl, et al. (2007) Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 92 110-116.
401. PW Speiser, J Serrat, MI New, et al. (1992) Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 75 1421-1424.
402. P Sartorato, E Zulian, S Benedini, et al. (2007) Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 92 1015-1018.
403. EF Roche, E Charmandari, MT Dattani, et al. (2003) Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol 58 589-596.
404. TMK Volkl, D Simm, J Dotsch, et al. (2006) Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 91 4888-4895.
405. PC White, KM Curnow and L Pascoe (1994) Disorders of steroid 11 β-hydroxylase isozymes. Endocr Rev 15 421-438.
406. K Joehrer, S Geley, EM Strasser-Wozak, et al. (1997) CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 β-hydroxylase deficiency. Hum Mol Genet 6 1829-1834.
407. CJ Peters, T Nugent, LA Perry, et al. (2007) Cosegregation of a novel homozygous CYP11B1 mutation with the phenotype of non-classical congenital adrenal hyperplasia in a consanguineous family. Horm Res 67 189-193.
408. M Peter, N Janzen, S Sander, et al. (2008) A case of 11β-hydroxylase deficiency detected in a newborn screening program by second-tier LC-MS/MS. Horm Res 69 253-256.
409. S Pang, LS Levine, F Lorenzen, et al. (1980) Hormonal studies in obligate heterozygotes and siblings of patients with 11 β-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 50 586-589.
410. JL Gabrilove, DC Sharma and RI Dorfman (1965) Adrenocortical 11-β-hydroxylase deficiency and virilism first manifest in the adult women. N Engl J Med 272 1189-1194.
411. G de Simone, AP Tommaselli, R Rossi, et al. (1985) Partial deficiency of adrenal 11-hydroxylase: a possible cause of primary hypertension. Hypertension 7 204-210.
412. EG Biglieri (1997) 17 Alpha-hydroxylase deficiency: 1963-1966. J Clin Endocrinol Metab 82 48-50.
413. M Zachmann, EA Werder and A Prader (1982) Two types of male pseudohermaphroditism due to 17, 20-desmolase deficiency. J Clin Endocrinol Metab 55 487-490.
414. RJ Auchus (2001) The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 30 101-119. vii
415. DH Geller, RJ Auchus and WL Miller (1999) P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol 13 167-175.
416. RJ Auchus, TC Lee and WL Miller (1998) Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 273 3158-3165.
417. T Yanase, ER Simpson and MR Waterman (1991) 17 Alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 12 91-108.
418. DH Geller, RJ Auchus, BB Mendonca, et al. (1997) The genetic and functional basis of isolated 17,20/lyase deficiency. Nat Genet 17 201-205.
419. DP Sherbet, D Tiosano, KM Kwist, et al. (2003) CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J Biol Chem 278 48563-48569.
420. RE Peterson, J Imperato-McGinley, T Gautier, et al. (1985) Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases: a new variant of congenital adrenal hyperplasia. N Engl J Med 313 1182-1191.
421. C Shackleton, J Marcos, W Arlt, et al. (2004) Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet 129A 105-112.
422. DL Cragun, SK Trumpy, CH Shackleton, et al. (2004) Undetectable maternal serum uE3 and postnatal abnormal sterol and steroid metabolism in Antley-Bixler syndrome. Am J Med Genet 129A 1-7.
423. M Fukami, T Hasegawa, R Horikawa, et al. (2006) Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 59 276-280.
424. CE Fluck, T Tajima, AV Pandey, et al. (2004) Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36 228-230.
425. W Arlt, EA Walker, N Draper, et al. (2004) Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363 2128-2135.
426. K Homma, T Hasegawa, T Nagai, et al. (2006) Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 91 2643-2649.
427. M Fukami, G Nishimura, K Homma, et al. (2009) Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 94 1723-1731.
428. N Huang, AV Pandey, V Agrawal, et al. (2005) Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76 729-749.
429. DM Otto, CJ Henderson, D Carrie, et al. (2003) Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 23 6103-6116.
430. E Rheaume, J Simard, Y Morel, et al. (1992) Congenital adrenal hyperplasia due to point mutations in the type II 3 β-hydroxysteroid dehydrogenase gene. Nat Genet 1 239-245.
431. J Simard, M-L Ricketts, S Gingras, et al. (2005) Molecular biology of the 3β-hydroxysteroid dehydrogenase/δ5-δ4 isomerase gene family. Endocr Rev 26 525-582.
432. S Marui, M Castro, AC Latronico, et al. (2000) Mutations in the type II 3β-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clin Endocrinol (Oxf) 52 67-75.
433. SY Pang, AJ Lerner, E Stoner, et al. (1985) Late-onset adrenal steroid 3 β-hydroxysteroid dehydrogenase deficiency: I. A cause of hirsutism in pubertal and postpubertal women. J Clin Endocrinol Metab 60 428-439.
434. C Lutfallah, W Wang, JI Mason, et al. (2002) Newly proposed hormonal criteria via genotypic proof for type II 3β-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 87 2611-2622.
435. LM Mermejo, LLK Elias, S Marui, et al. (2005) Refining hormonal diagnosis of type II 3β-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 90 1287-1293.
436. HS Bose, T Sugawara, JF Strauss 3rd, et al. (1996) The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med 335 1870-1878.
437. BY Baker, L Lin, CJ Kim, et al. (2006) Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 91 4781-4785.
438. T Tajima, K Fujieda, N Kouda, et al. (2001) Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 86 3820-3825.
439. O Hiort, PM Holterhus, R Werner, et al. (2005) Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex. J Clin Endocrinol Metab 90 538-541.
440. CJ Kim, L Lin, N Huang, et al. (2008) Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 93 696-702.
441. P Rubtsov, M Karmanov, P Sverdlova, et al. (2009) A novel homozygous mutation in CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46,XY patient. J Clin Endocrinol Metab 94 936-939.
442. A Jamieson, AM Wallace, R Andrew, et al. (1999) Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 84 3570-3574.
443. GG Lavery, EA Walker, A Tiganescu, et al. (2008) Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 93 3827-3832.
444. DA Vassiliadi, TM Barber, BA Hughes, et al. (2009) Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 94 3558-3566.
445. JD Veldhuis and JC Melby (1981) Isolated aldosterone deficiency in man: acquired and inborn errors in the biosynthesis or action of aldosterone. Endocr Rev 2 495-517.
446. PC White (2004) Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol 217 81-87.
447. KM Kayes-Wandover, RE Schindler, HC Taylor, et al. (2001) Type 1 aldosterone synthase deficiency presenting in a middle-aged man. J Clin Endocrinol Metab 86 1008-1012.
448. MC Zennaro and M Lombes (2004) Mineralocorticoid resistance. Trends Endocrinol Metab 15 264-270.
449. DS Geller, J Rodriguez-Soriano, A Vallo Boado, et al. (1998) Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 19 279-281.
450. SS Chang, S Grunder, A Hanukoglu, et al. (1996) Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 12 248-253.
451. SS Strautnieks, RJ Thompson, RM Gardiner, et al. (1996) A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet 13 248-250.
452. A Hanukoglu, O Joy, M Steinitz, et al. (1997) Pseudohypoaldosteronism due to renal and multisystem resistance to mineralocorticoids respond differently to carbenoxolone. J Steroid Biochem Mol Biol 60 105-112.
453. FH Wilson, S Disse-Nicodeme, KA Choate, et al. (2001) Human hypertension caused by mutations in WNK kinases. Science 293 1107-1112.
454. RA DeFronzo (1980) Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 17 118-134.
455. FS Sunderlin Jr, GH Anderson Jr, DH Streeten, et al. (1981) The renin-angiotensin-aldosterone system in diabetic patients with hyperkalemia. Diabetes 30 335-340.
456. JL Gabrilove, AT Seman, R Sabet, et al. (1981) Virilizing adrenal adenoma with studies on the steroid content of the adrenal venous effluent and a review of the literature. Endocr Rev 2 462-470.
457. RT Kloos, MD Gross, IR Francis, et al. (1995) Incidentally discovered adrenal masses. Endocr Rev 16 460-484.
458. M Terzolo, S Bovio, G Reimondo, et al. (2005) Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 34 423-439. x
459. B Catargi, V Rigalleau, A Poussin, et al. (2003) Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 88 5808-5813.
460. D Flecchia, E Mazza, M Carlini, et al. (1995) Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour. Clin Endocrinol (Oxf) 42 129-134.
461. TJ Cawood, PJ Hunt, D O'Shea, et al. (2009) Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant: time for a rethink? Eur J Endocrinol 161 513-527.
462. G Mansmann, J Lau, E Balk, et al. (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25 309-340.
463. C Gicquel, Y Le Bouc, JP Luton, et al. (1998) Pathogenesis and treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diab 5 189-196.
464. MM Matzuk, MJ Finegold, JP Mather, et al. (1994) Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci U S A 91 8817-8821.